Kim Kelderman - 27 Jan 2025 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.
Issuer symbol
TECH
Transactions as of
27 Jan 2025
Transactions value $
$-530,135
Form type
4
Filing time
29 Jan 2025, 16:35:39 UTC
Previous filing
05 Nov 2024
Next filing
17 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $504,878 +13,392 +34.3% $37.70 52,396 27 Jan 2025 Direct
transaction TECH Common Stock Sale $-905,533 -11,731 -22.4% $77.19 40,665 27 Jan 2025 Direct F1
transaction TECH Common Stock Sale $-129,480 -1,661 -4.08% $77.95 39,004 27 Jan 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Option (Right to Buy) Options Exercise $0 -13,392 -100% $0.000000 0 27 Jan 2025 Common Stock 13,392 $37.70 Direct F3
holding TECH Stock Option (Right to Buy) 84,308 27 Jan 2025 Common Stock 84,308 $44.33 Direct F3
holding TECH Stock Option (Right to Buy) 109,536 27 Jan 2025 Common Stock 109,536 $47.60 Direct F3
holding TECH Stock Option (Right to Buy) 115,724 27 Jan 2025 Common Stock 115,724 $66.97 Direct F3
holding TECH Stock Option (Right to Buy) 25,944 27 Jan 2025 Common Stock 25,944 $120.46 Direct F4
holding TECH Performance Restricted Stock Units 6,984 27 Jan 2025 Common Stock 6,984 Direct F5, F6
holding TECH Performance Stock Options (Right to Buy) 21,704 27 Jan 2025 Common Stock 21,704 $94.52 Direct F6
holding TECH Stock Options (Right to Buy) 28,940 27 Jan 2025 Common Stock 28,940 $94.52 Direct F7
holding TECH Performance Restricted Stock Units 8,873 27 Jan 2025 Common Stock 8,873 Direct F5, F8
holding TECH Performance Stock Options (Right to Buy) 23,881 27 Jan 2025 Common Stock 23,881 $84.61 Direct F8
holding TECH Stock Options (Right to Buy) 29,391 27 Jan 2025 Common Stock 29,391 $84.61 Direct F9
holding TECH Stock Options (Right to Buy) 38,252 27 Jan 2025 Common Stock 38,252 $52.83 Direct F10
holding TECH Performance Restricted Stock Units 9,423 27 Jan 2025 Common Stock 9,423 Direct F5, F8
holding TECH Performance Stock Options (Right to Buy) 25,945 27 Jan 2025 Common Stock 25,945 $68.54 Direct F8
holding TECH Stock Options (Right to Buy) 51,890 27 Jan 2025 Common Stock 51,890 $68.54 Direct F11
holding TECH Performance Restricted Stock Units 51,261 27 Jan 2025 Common Stock 51,261 Direct F5, F12
holding TECH Restricted Stock Units 25,630 27 Jan 2025 Common Stock 25,630 Direct F5, F13
holding TECH Stock Options (Right to Buy) 69,061 27 Jan 2025 Common Stock 69,061 $74.91 Direct F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.67 to $77.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.69 to $78.08 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Fully exercisable.
F4 Options to purchase 6,484 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 6,488 shares vest on each of 8/6/2024 and 8/6/2025.
F5 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F6 Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7 Options to purchase 7,236 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025.
F8 Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9 Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
F10 Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
F11 Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
F12 Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F13 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
F14 Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.